gsk201501196k3.htm
FORM 6-K/A
 
 
SECURITIES AND EXCHANGE COMMISSION

Washington D.C. 20549
 
 
Report of Foreign Issuer
 
 
Pursuant to Rule 13a-16 or 15d-16 of

athe Securities Exchange Act of 1934
 
 
 
For period ending January 2015
 
GlaxoSmithKline plc
(Name of registrant)


 
 
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address of principal executive offices)


 
 
Indicate by check mark whether the registrant files or
will file annual reports under cover Form 20-F or Form 40-F


 
 
Form 20-F x     Form 40-F

 
--

 
Indicate by check mark whether the registrant by furnishing the
information contained in this Form is also thereby furnishing the
information to the Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934.


 
 
Yes      No x
--

 
 

 
GlaxoSmithKline plc
 
Notification of Transactions of Directors, Persons Discharging Managerial Responsibility or Connected Persons
 
In accordance with DTR 3.1.4R(1)(a) and (c) GlaxoSmithKline plc ('GSK') was advised on 19 January 2015, of changes in the interests of the following Directors and Persons Discharging Managerial Responsibilities, following increases in interests in Ordinary Shares ('Shares'), at a price of 1420.57 pence per Share on 8 January 2015, following the re-investment of the dividend paid to shareholders on 8 January 2015.
 
 
 
Director/PDMR
 
 
Shares
Sir Andrew Witty
1,544.610
Mr R G Connor
91.618
Mr S Dingemans
666.940
Mr S A Hussain
1,831.014
Mr D S Redfern
670.949
Dr M M Slaoui
149.766
Ms C Thomas
817.766
Mr P C Thomson
264.686
Dr P J T Vallance
923.872
Ms E Walmsley
749.475

 
 
Connected Person
 
Shares
Mrs K Thomson (connected person toMr P C Thomson)
          62.242
 
 
V A Whyte
Company Secretary
 
19 January 2015
 
 

 

 



  
SIGNATURES
 
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.



 
 
GlaxoSmithKline plc
(Registrant)


Date: January 19, 2015 
 
 
By: VICTORIA WHYTE
----------------------
 
 
Victoria Whyte
Authorised Signatory for and on
behalf of GlaxoSmithKline plc